<DOC>
	<DOCNO>NCT02327039</DOCNO>
	<brief_summary>In Phase 2b/3 clinical trial , Dapagliflozin show raise HDL cholesterol level 4 mg/dl ( 1 mmol/l ) , generally consider clinically-meaningful change . As HDL cholesterol increase carry concomitant improvement glucotoxicity body weight reduction , possible treatment Dapagliflozin also improve HDL function . This important clinical , epidemiological experimental study indicate HDL function may important HDL cholesterol level determine protective cardiovascular effect HDL particle . In addition , know effect Dapagliflozin HDL function help interpret increase HDL cholesterol level observe Dapagliflozin-treated patient . Finally , discovery extra-glycemic effect Dapagliflozin shed new light potential benefit therapy Dapagliflozin SGLT2i general . So far , study evaluate effect Dapagliflozin ( SGLT2i ) HDL function . The investigator hypothesize Dapagliflozin , addition raise HDL cholesterol level , also increase HDL functionality , measure reverse cholesterol transport anti-oxidant capacity , patient T2DM</brief_summary>
	<brief_title>The Effects Dapagliflozin HDL Particles Subtypes Reverse Cholesterol Transport Type 2 Diabetic Patients</brief_title>
	<detailed_description>Sodium glucose co-transport-2 ( SGLT-2 ) inhibitor ( SGLT-2i ) , new class glucose-lowering agent , reduce tubular glucose reabsorption , thus lower blood glucose without stimulate insulin release . SGLT-2i find effective improve glucose control type 2 diabetic patient disease stage , also add insulin type 1 diabetic patient . In addition glycosuric effect , SGLT-2i reduce body weight blood pressure determine increase HDL cholesterol level . HDL mediate reverse cholesterol transport , extract cholesterol peripheral tissue cell vehiculating liver . This function , regulate enzyme cholesteryl esther transfer protein ( CETP ) , consider fundamental mechanism protection accumulation cholesterol vasculature physiologic barrier atherosclerosis development protection . The sophisticated method precisely assess reverse cholesterol transport vitro available research lab . Although report therapy SGLT-2i raise HDL concentration 4 mg/dL ( 0.1 mmol/L ) , mechanism remain unclear important ass whether quantitative increase couple functional improvement reverse cholesterol transport . In fact , previous study HDL-raising therapy clarify HDL particle functional HDL cholesterol level might representative reverse cholesterol transport process . In addition cholesterol transport , normal HDL particle also anti-oxidant anti-inflammatory property , important translate HDL cholesterol level cardiovascular protection . Several HDL subclass identify , different composition anti-atherosclerotic property . Dapagliflozin ( Bristol-Myers Squibb Company [ BMS ] -512148 ) highly potent , selective , reversible inhibitor sodium-glucose cotransporter 2 ( SGLT2 ) , major transporter responsible renal glucose reabsorption . Dapagliflozin lower plasma glucose inhibit renal reabsorption glucose promote urinary excretion . A tablet formulation dapagliflozin oral administration approve 40 country include European Union ( EU ) United States ( US ) review numerous country around world . Dapagliflozin approve AIFA determination number 909/2013 date 16/10/2013 , marketing authorization number 042494070/E . In Phase 2b 3 program , dapagliflozin study monotherapy combination metformin , pioglitazone , glimepiride , sitagliptin , insulin . As 15-Nov-2012 ( date recent pooled analysis ) , total 9,412 subject T2DM treat 16 Phase 3 , double-blind , control clinical study conduct evaluate safety efficacy dapagliflozin ; 5,952 subject study treat dapagliflozin 80 week . The Phase 2b 3 program establish dapagliflozin effective reduce HbA1c broad range subject regardless disease progression/duration concomitant use antidiabetic therapy . Improvements glycemic control see dapagliflozin give monotherapy ; add-on combination therapy sitagliptin metformin , sulfonylurea ( glimepiride ) , thiazolidinedione ( pioglitazone ) , insulin ( ± oral antidiabetic drug [ OADs ] ) ; initial combination therapy metformin . HDL level function . Observational study provide overwhelm evidence low high-density lipoprotein ( HDL ) -cholesterol level increase risk coronary event , healthy subject patient coronary heart disease . Based vitro experiment , several mechanistic explanation atheroprotective function HDL suggest . The HDL function currently widely hold account antiatherogenic effect include participation reverse cholesterol transport , protection endothelial dysfunction , inhibition oxidative stress . Yet , several recent pharmacological genetic study fail demonstrate increase plasma level HDL-C result decreased cardiovascular disease risk , give rise controversy regard whether plasma level HDL-C reflect HDL function , HDL even protective assume . The evidence preclinical clinical study show HDL promote regression atherosclerosis level functional particle increase endogenous exogenous source . The data show regression result combination reduce plaque lipid macrophage content , well reduction inflammatory state . Although research need regard basic mechanism establish change translate clinically reduce cardiovascular disease event , HDL regress plaque suggest recent trial failure eliminate HDL consideration atheroprotective agent rather emphasize important distinction HDL function plasma level HDL-C . While HDL healthy subject directly stimulate endothelial cell production nitric oxide anti-inflammatory , anti-apoptotic , anti-thrombotic effect well endothelial repair process , grow evidence suggest vascular effect HDL highly heterogeneous vasoprotective property HDL alter patient coronary disease . In fact , HDL show undergo loss function several pathophysiological state , acute phase response , obesity chronic inflammatory disease . Some disease also show associate increase risk cardiovascular disease . One disease associate HDL dysfunction accelerate atherosclerosis diabetes mellitus , disease HDL particle undergoes diverse structural modification result significant change function , glycation oxidation . In Phase 2b/3 clinical trial , Dapagliflozin show raise HDL cholesterol level 4 mg/dl ( 1 mmol/l ) , generally consider clinically-meaningful change . As HDL cholesterol increase carry concomitant improvement glucotoxicity body weight reduction , possible treatment Dapagliflozin also improve HDL function . This important clinical , epidemiological experimental study indicate HDL function may important HDL cholesterol level determine protective cardiovascular effect HDL particle . In addition , know effect Dapagliflozin HDL function help interpret increase HDL cholesterol level observe Dapagliflozin-treated patient . Finally , discovery extra-glycemic effect Dapagliflozin shed new light potential benefit therapy Dapagliflozin SGLT2i general . So far , study evaluate effect Dapagliflozin ( SGLT2i ) HDL function.We hypothesize Dapagliflozin , addition raise HDL cholesterol level , also increase HDL functionality , measure reverse cholesterol transport anti-oxidant capacity , patient T2DM . This randomized , placebo control , parallel group study 36 type 2 diabetic patient assess effect Dapagliflozin HDL level function . The general objective project detect significant difference change versus baseline patient ' HDL cholesterol efflux capacity , HDL level , HDL subclasses , HDL anti-oxidant activity , CETP activity , serum/plasma cytokine adipokines ( IL-6 , IL-8 , PAI-1 , TNF-α , visfatin , resistin , adiponectin , leptin ) patient randomize dapagliflozin compare randomize placebo</detailed_description>
	<criteria>Provision inform consent prior study specific procedure Female male subject age 1875 year Type 2 diabetes oral agent +/ insulin Diabetes duration &gt; 6 month HbA1c 7.010.0 % Acute illness infection Recent ( within 1 month ) surgery , trauma , cardiovascular event Recent ( within 3 month ) variation statin therapy/dose Therapy HDLmodifying drug , fibrates , omega3 fatty acid , niacin Alcoholism Very high baseline HDL level ( &gt; 90 mg/dL ) Previous history recurrent ( ≥2 episodes ) urinary tract infection genital infection ( single remote episode consider exclusion criterion ) History hypotension , episodes volume depletion / dehydration . Chronic renal failure ( eGFR &lt; 60 ml/min/1.73 mq ) Chronic liver disease ( SGOT GPT &gt; 2fold ULN , cirrhosis ) Elevated hematocrit ( &gt; 50 % men &gt; 45 % woman ) Heart failure , NYHA class IIIIV Hypersensitivity Dapagliflozin excipients Treatment pioglitazone GLP1 receptor agonist Women childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>